Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CALML3 | P27482 | 1/20 | 0.34 |
| ▸ | SDHA | P31040 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336363 | 0.88 | MAOA (0.41) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6335891 | 0.86 | MAOA (0.47) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6337001 | 0.84 | MAOA (0.43) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6335763 | 0.81 | MAOA (0.50) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6348267 | 0.81 | MAOA (0.50) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6335767 | 0.81 | MAOA (0.50) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6425567 | 0.78 | MAOA (0.35) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6767679 | 0.75 | GRM2 (0.40) | F10CALML3 | |
| SCHEMBL6337532 | 0.74 | CETP (0.44) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6423688 | 0.73 | MAOA (0.37) | F10MAOAMAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203144-A1 | Bicyclo[3.1.0]hexane containing oxazolidinone antibiotics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203144-A1 | Bicyclo[3.1.0]hexane containing oxazolidinone antibiotics and derivatives thereof | NR0B1, NR4A1, VDR | F10 3573/4885ITGB3 1750/4885ITGA2B 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.